Business Context and Reporting Period
Sionna Therapeutics, Inc. (Nasdaq: SION) is a clinical-stage biopharmaceutical company focused on developing novel medicines for cystic fibrosis (CF). The company targets the NBD1 domain of the CFTR protein, a mechanism distinct from current standard-of-care therapies. This Form 10-K covers the fiscal year ended December 31, 2025. The company completed its Initial Public Offering (IPO) in February 2025, raising approximately $199.6 million in net proceeds.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(75.3) million | $(61.7) million |
| Operating Expenses | $89.0 million | $70.6 million |
| Research & Development (R&D) | $60.3 million | $57.3 million |
| General & Administrative (G&A) | $28.7 million | $13.3 million |
| Cash, Cash Equivalents & Marketable Securities | $310.3 million | $168.0 million |
| Accumulated Deficit | $(256.4) million | $(181.1) million |
| Net Cash Used in Operating Activities | $(66.3) million | $(52.8) million |
Note: The company has no debt obligations as of December 31, 2025. Liquidity is supported by cash and marketable securities.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose by $18.4 million (26%) year-over-year. This was driven primarily by a $15.5 million increase in G&A expenses due to public company costs and personnel growth, and a $3.0 million increase in R&D expenses due to expanded clinical activities.
- Capital Raise: The company transitioned from private to public status in February 2025, converting all preferred stock to common stock and raising $199.6 million in net proceeds. This significantly increased cash reserves from $168.0 million in 2024 to $310.3 million in 2025.
- Interest Income: Interest income increased by $5.1 million to $13.3 million, reflecting higher investment balances from IPO proceeds.
- One-Time Costs: 2024 included a $13.6 million non-cash expense related to the acquisition of in-process research and development (IPR&D) from AbbVie, which was not present in 2025.
Guidance, Outlook, and Risks
Outlook and Guidance: Management believes current cash resources ($310.3 million) are sufficient to fund operations into 2028. The company anticipates continued significant operating losses as it advances clinical trials. No specific financial guidance was provided beyond the runway estimate.
Key Clinical Milestones:
- SION-719: Initiated Phase 2a proof-of-concept trial (PreciSION CF) in October 2025 as an add-on to standard of care. Topline data expected mid-2026.
- SION-451: Initiated Phase 1 dual combination trial with SION-2222 and SION-109 in August 2025. Topline data expected mid-2026.
Material Risks:
- Dependence on NBD1 Stabilizers: Success is heavily reliant on the clinical performance of SION-719 and SION-451.
- Need for Additional Capital: The company will require substantial additional funding to complete development and commercialization. Failure to raise capital could force delays or program termination.
- Regulatory and Clinical Uncertainty: As a clinical-stage company with no approved products, there is no guarantee of regulatory approval or commercial success.
- Competition: Vertex Pharmaceuticals holds substantial market share in the CF market with approved therapies (Trikafta, Alyftrek).
Investor Verification Checklist
- Cash Runway: Verify the $310.3 million cash balance and the assumption that it funds operations into 2028.
- Clinical Trial Enrollment: Monitor enrollment rates and safety data for the PreciSION CF (SION-719) and SION-451 combination trials, with data readouts expected mid-2026.
- Licensing Obligations: Review milestone payment triggers under agreements with Sanofi (up to $40M), CFF (up to $40M), and AbbVie (up to $360M).
- Expense Trajectory: Track the growth of G&A expenses as the company scales its public company infrastructure.
- Regulatory Status: Confirm FDA acceptance of data from foreign clinical trials (e.g., Australia) and any potential regulatory holds.